<DOC>
	<DOCNO>NCT01362296</DOCNO>
	<brief_summary>This phase II , open-label , multicenter , randomize study evaluate efficacy safety GSK1120212 compare docetaxel second line set subject locally advance metastatic ( Stage IV ) Non-small cell lung cancer ( NSCLC ) harbor KRAS mutation fail one platinum-containing chemotherapy regimen . A small subset NSCLC subject harbor BRAF , NRAS , MEK1 mutation randomize addition primary KRAS population , exploratory purpose .</brief_summary>
	<brief_title>An Open-label Study GSK1120212 Compared With Docetaxel Stage IV KRAS-mutant Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<criteria>At least 18 year old histologically cytologicallyconfirmed diagnosis adenocarcinoma Stage IV NSCLC positive mutational status KRAS , NRAS , BRAF , MEK1 gene . Documented tumor progression receive least one , one , prior approve platinumcontaining chemotherapy regimen advance stage/metastatic NSCLC . Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 . Performance status score 0 1 accord Eastern Cooperative Oncology Group ( ECOG ) scale . Able swallow retain orally administer medication clinically significant gastrointestinal abnormality may alter absorption malabsorption syndrome major resection stomach bowel . Life expectancy least three month opinion investigator . Women childbearing potential must negative serum pregnancy test within 14 day randomization study treatment agree use effective contraception . Men female partner childbearing potential must either prior vasectomy agree use effective contraception time randomization study medication least four week last dose study treatment . Adequate baseline organ function . History another malignancy . Any serious and/or unstable preexist medical disorder , psychiatric disorder , condition could interfere subject 's safety , obtain informed consent compliance study procedure . Treatment BRAF MEK inhibitor docetaxel monotherapy part combination regimen . Anticancer therapy ( include chemotherapy radiation therapy ) within last three week . History current evidence / risk retinal vein occlusion central serous retinopathy . Any current history tumor manifestation Central Nervous System . History evidence cardiovascular risk , include QTcB &gt; =480 msec , uncontrolled arrhythmia , acute coronary syndrome , coronary angioplasty , stenting within 6 month prior randomization , &gt; =Class II congestive heart failure , treatment refractory hypertension , intracardiac defibrillator permanent pacemaker cardiac metastasis . Known Human Immunodeficiency Virus , Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HBC ) infection ( exception chronic clear HBV HCV infection ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>NRAS</keyword>
	<keyword>docetaxel</keyword>
	<keyword>NSCLC</keyword>
	<keyword>GSK1120212</keyword>
	<keyword>MEK inhibitor</keyword>
	<keyword>target therapy</keyword>
	<keyword>KRAS</keyword>
	<keyword>BRAF</keyword>
</DOC>